BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26548424)

  • 1. Predictive validation of modeled health technology assessment claims: lessons from NICE.
    Belsey J
    J Med Econ; 2015; 18(12):1007-12. PubMed ID: 26548424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The status of modeled claims.
    Langley PC
    J Med Econ; 2015; 18(12):991-2. PubMed ID: 26549706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of modeled pharmacoeconomic claims in formulary submissions.
    Langley PC
    J Med Econ; 2015; 18(12):993-9. PubMed ID: 26549802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 5. A cure for old age. Why NHS must act now to save the deteriorating asset base.
    Health Serv J; 2013 Nov; 123(6376):19. PubMed ID: 24416973
    [No Abstract]   [Full Text] [Related]  

  • 6. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansley is right: age trumps poverty.
    Asthana S
    Health Serv J; 2012 May; 122(6306):16-7. PubMed ID: 22741385
    [No Abstract]   [Full Text] [Related]  

  • 8. The NHS must build resilience.
    Heitmueller A
    Health Serv J; 2014 May; 124(6400):16-8. PubMed ID: 25137754
    [No Abstract]   [Full Text] [Related]  

  • 9. Prioritizing health technologies in a Primary Care Trust.
    Wilson E; Sussex J; Macleod C; Fordham R
    J Health Serv Res Policy; 2007 Apr; 12(2):80-5. PubMed ID: 17407656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disinvestment from low value clinical interventions: NICEly done?
    Garner S; Littlejohns P
    BMJ; 2011 Jul; 343():d4519. PubMed ID: 21795239
    [No Abstract]   [Full Text] [Related]  

  • 12. AHRQ's free research can help plans anticipate coverage issues.
    Roberts DC; Schoelles K
    Manag Care; 2013 Oct; 22(10):41-4. PubMed ID: 24344527
    [No Abstract]   [Full Text] [Related]  

  • 13. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
    Andronis L; Barton P; Bryan S
    Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choosing between competing health priorities. A government payer perspective.
    Leese J
    Pharmacoeconomics; 1996; 9 Suppl 3():4-7; discussion 23-5. PubMed ID: 10160486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION.
    Tordrup D; Chouaid C; Cuijpers P; Dab W; van Dongen JM; Espin J; Jönsson B; Léonard C; McDaid D; McKee M; Miguel JP; Patel A; Reginster JY; Ricciardi W; Rutten-van Molken M; Rupel VP; Sach T; Sassi F; Waugh N; Bertollini R
    Int J Technol Assess Health Care; 2017 Jan; 33(6):609-619. PubMed ID: 29081308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational health economics: The key to accountable adoption of in vitro diagnostic technologies.
    Price CP; Wolstenholme J; McGinley P; St John A
    Health Serv Manage Res; 2018 Feb; 31(1):43-50. PubMed ID: 29084478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
    Mullahy J
    Med Care; 1996 Dec; 34(12 Suppl):DS124-35. PubMed ID: 8969321
    [No Abstract]   [Full Text] [Related]  

  • 20. Defining types of economic evaluation.
    Ngorsuraches S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S21-7. PubMed ID: 19255985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.